Express Scripts
Express Scripts is one of the three largest pharmacy benefit managers (PBMs) in the United States, processing approximately 24% of all prescription claims. Owned by The Cigna Group since 2018, it manages drug formularies, negotiates manufacturer rebates, operates mail-order and specialty pharmacies, and administers prescription benefits for over 100 million members. In February 2026, Express Scripts reached a landmark FTC settlement requiring structural reforms to its rebate and formulary practices.
Score generated by AI agents based on publicly cited evidence and reviewed by the project maintainer. Not independently validated.
Score History
Timeline events are AI-curated from public reporting. Score trajectory is derived from documented events.
Express Scripts was founded as a small joint venture between Medicare Glaser and Sanus Corp in St. Louis to manage prescription drug benefits. The PBM industry was nascent and competitive, with no single player holding significant market share. Pricing practices were simple and relatively transparent, with Express Scripts processing a fraction of the claims it would later handle.
After going public in 1992 under New York Life ownership and executing the $445 million ValueRx and $700 million Diversified Pharmaceutical Services acquisitions, Express Scripts became the third-largest U.S. PBM managing nearly $10 billion in drug spending. The rapid consolidation era introduced the spread pricing and rebate negotiation practices that would later define PBM extraction. Formulary management was growing more aggressive, and the company's revenue surged from $27 million in 1990 to $6.8 billion by 2000.
The $29.1 billion acquisition of Medco Health Solutions in April 2012 created the nation's dominant PBM, processing over 1.4 billion prescriptions annually. FTC Commissioner Brill dissented, calling it a 'merger to duopoly,' but the deal was approved without conditions. Express Scripts launched its formulary exclusion program in 2014 and settled a $9.3 million deceptive practices case with 29 states. The company's market power over both pharmacies and manufacturers increased sharply as PBM consolidation reduced competitive pressure.
Cigna's $67 billion acquisition of Express Scripts closed in December 2018, creating a vertically integrated entity controlling insurance, formulary decisions, claims processing, and pharmacy dispensing. The Anthem $15 billion lawsuit had exposed systematic overcharging, and DIR fee clawbacks were escalating exponentially. Formulary exclusions had grown from 48 drugs in 2014 to 159 by 2018. The merger deepened conflicts of interest while regulatory oversight remained minimal as the DOJ approved the deal without conditions.
Under the Evernorth rebrand, Express Scripts reached peak extraction through offshore GPO operations in Switzerland, systematic TRICARE over-dispensing exposed by a whistleblower lawsuit, and the expulsion of nearly 15,000 pharmacies from the TRICARE network over reimbursement disputes affecting 400,000 military families. The Express Scripts-Prime Therapeutics collaboration further concentrated market power. Specialty drug markups of hundreds to thousands of percent generated over $7.3 billion in excess revenue across the industry from 2017-2022.
The FTC launched its landmark enforcement action against Express Scripts and two other PBMs in September 2024, alleging anticompetitive rebating practices that inflated insulin prices. Express Scripts counter-sued the FTC and challenged its constitutional authority. Simultaneously, opioid crisis lawsuits from Kentucky, West Virginia, and Philadelphia targeted PBMs' role in facilitating overdispensing. State PBM reform legislation swept through all 50 states. Cigna's $10 billion buyback authorization and $7 billion in annual repurchases continued unabated.
The February 2026 FTC settlement requires Express Scripts to eliminate spread pricing, pass rebates through to patients by 2028, adopt cost-plus pharmacy reimbursement, and reshore its Swiss GPO — representing the most significant structural reform ever imposed on a PBM. However, the settlement carries no financial penalties and allows multi-year transition periods. Cigna simultaneously cut 2,000 jobs while executing $9-10 billion in annual buybacks and paying CEO Cordani $23.3 million. The regulatory and legal pressure is unprecedented, but operational extraction continues during the transition.
Alternatives
Transparent-pricing pharmacy that sells generics at cost plus a 15% markup, completely bypassing PBM middlemen including Express Scripts. For many common generics, the cash price is dramatically lower than what Express Scripts charges your plan. Easy to use — check the site, have your prescription sent there, and pay directly. Does not cover specialty drugs or brand-name medications.
Free discount card that negotiates lower cash prices at most retail pharmacies, often undercutting your Express Scripts copay — especially useful if you're being steered to Express Scripts' mail-order pharmacy. Worth checking before every fill by showing the coupon at any participating pharmacy. GoodRx has its own data monetization issues (scored 49), but as a tool to escape PBM pricing on specific prescriptions it is genuinely useful.
Dimensional Breakdown
Summaries below were written by AI agents based on the cited evidence. They are editorial interpretations, not independent research findings.
Dimension History
Timeline (43 events)
Express Scripts founded as joint venture PBM
Express Scripts was created as a joint venture between Medicare Glaser Inc. (a chain of 79 pharmacies) and Sanus Corp. Health Systems in St. Louis, Missouri. The new company was formed to manage prescription drug benefits, entering a nascent PBM industry that would later come to dominate pharmaceutical distribution.
New York Life Insurance acquires Express Scripts
New York Life Insurance Company purchased Express Scripts, providing capital for growth. NYLife Healthcare Management, a subsidiary, would retain controlling interest through a dual-class share structure even after the company went public in 1992.
Express Scripts IPO on NASDAQ raises $28 million
Express Scripts went public on the NASDAQ exchange, raising more than $28 million. New York Life retained controlling interest through Class B shares with 10 votes per share, while public Class A shares had one vote each. Stock rose from $13 IPO price to $35.25 early in 1993.
Express Scripts acquires ValueRx for $445 million
Express Scripts purchased ValueRx, the PBM business of Columbia/HCA Healthcare Corp., for $445 million, becoming the largest independent U.S.-based pharmacy benefit manager. The acquisition expanded claims processing and formulary management scale significantly, giving the combined entity greater leverage over pharmacy reimbursement rates and employer plan negotiations. Patients began experiencing more restrictive formularies as the combined entity's scale enabled more aggressive drug coverage decisions.
Diversified Pharmaceutical Services acquired for $700 million
Express Scripts purchased Diversified Pharmaceutical Services from SmithKline Beecham Corp for $700 million in cash. The deal secured Express Scripts' position as the third-largest PBM overall in the U.S., managing nearly $10 billion in drug spending annually. The combined entity's scale gave it power to restrict formularies, impose mail-order requirements, and set pharmacy network terms that limited patient and employer choice.
NY Attorney General Spitzer sues Express Scripts over retained rebates
New York Attorney General Eliot Spitzer filed a lawsuit against Express Scripts alleging the company kept tens of millions of dollars in drug manufacturer rebates owed to the state and overstated cost benefits when urging doctors to switch patients to preferred medications. The case revealed Express Scripts' core monetization mechanism: negotiating rebates from manufacturers for formulary placement while retaining a portion rather than passing savings to plan sponsors or patients. The case was settled in 2008 for $9.3 million across 29 states.
George Paz becomes CEO, accelerating growth strategy
George Paz was named CEO of Express Scripts, succeeding Barrett Toan. Under Paz's leadership over the next 11 years, the company would grow from $15 billion to over $100 billion in revenue, executing the acquisitions and formulary strategies that would define the modern PBM model.
Express Scripts expands mandatory mail-order programs
Express Scripts aggressively expanded mandatory mail-order programs for employer clients, requiring employees to obtain maintenance medications exclusively through Express Scripts' mail-order pharmacy rather than retail pharmacies. The programs locked patients into Express Scripts' own dispensing channel and increased switching costs for employers, who faced penalties and higher per-prescription costs if they carved out the mail-order component. Independent pharmacies accused Express Scripts of 'slamming' — automatically transferring prescriptions without patient consent.
Data breach exposes up to 700,000 patient records
Express Scripts received an extortion letter containing personal data of 75 patients including Social Security numbers, birth dates, and prescription information. The FBI investigation ultimately revealed that up to 700,000 members' data may have been compromised, highlighting vulnerabilities in PBM data security.
Express Scripts pays $9.3 million to settle deceptive practices claims
Express Scripts settled with 29 state attorneys general, paying $9.3 million to resolve allegations that the company deceptively overstated cost savings when urging doctors to switch patients' medications. The company was not disclosing that the drug-switching revenue it earned would be retained rather than passed to health plans.
Express Scripts announces $29 billion Medco acquisition
Express Scripts announced a $29.1 billion deal to acquire Medco Health Solutions, combining two of the three largest U.S. pharmacy benefit managers. The acquisition would create the nation's dominant PBM, processing over 1.4 billion prescriptions annually. FTC Commissioner Julie Brill would later dissent, calling it a 'merger to duopoly.'
FTC approves Medco merger with 3-1 vote despite duopoly concerns
The FTC voted 3-1 to close its eight-month investigation and allow the Express Scripts-Medco merger to proceed without conditions. Commissioner Brill issued a dissent describing the deal as an industry 'game changer' creating a 'merger to duopoly' with CVS Caremark, 'with few efficiencies and high entry barriers.'
Express Scripts launches formulary exclusion program
Express Scripts began systematically excluding brand-name drugs from its National Preferred Formulary, starting with 48 drugs in 2014. The program would grow dramatically, reaching 159 excluded drugs by 2018. Express Scripts claimed the exclusions saved $2.5 billion for payors, but patients were forced to switch medications or pay full price out of pocket. Notifications were often opaque, arriving as dense letters that obscured whether alternatives existed or what costs patients would face.
DIR fee clawbacks begin escalating dramatically
Starting around 2016, PBMs including Express Scripts added performance-based DIR fees applied months after prescriptions were dispensed, clawing back reimbursement retroactively. Over the following decade, DIR fees increased by over 107,000%. These fees made it impossible for pharmacies to know their actual payment at time of dispensing.
Anthem sues Express Scripts for $15 billion over drug pricing
Anthem, Express Scripts' largest client accounting for 18% of revenue, filed a $15 billion lawsuit alleging the PBM overcharged Anthem by roughly $3 billion annually and failed to pass along drugmaker discounts. The dispute stemmed from a 10-year pricing contract signed in 2009 when Express Scripts bought Anthem's in-house PBM for $4.7 billion.
Cigna announces $67 billion Express Scripts acquisition
Cigna Corporation announced it would acquire Express Scripts in a $67 billion deal combining a major health insurer with the nation's largest PBM. The vertical integration would allow the combined entity to control insurance coverage, formulary decisions, claims processing, and pharmacy dispensing. Critics warned this created irreconcilable conflicts of interest.
Express Scripts closes Columbus pharmacy, lays off 456 workers
Express Scripts closed its Columbus, Ohio pharmacy facility, laying off 456 employees including 97 pharmacists. The closure was announced via a WARN Act notice filed in April 2018, just weeks after Cigna's acquisition announcement. While Express Scripts said the closure was unrelated to the Cigna deal, affected workers reported that the merger's $600 million in promised 'synergies' signaled further workforce cuts ahead.
DOJ approves Cigna-Express Scripts vertical merger
The Department of Justice Antitrust Division approved the Cigna-Express Scripts merger, determining the vertical combination was 'unlikely to result in harm to competition or consumers.' The deal closed on December 20, 2018 at approximately $54 billion, with Cigna also assuming $15 billion in Express Scripts debt.
Anthem drops Express Scripts, costing $20 billion in annual revenue
Anthem cut ties with Express Scripts 10 months ahead of schedule, launching its own PBM IngenioRx. The loss of Express Scripts' largest client — accounting for 18% of revenue and $2.25 billion in EBITDA — followed a bitter $15 billion lawsuit alleging systematic overcharging of roughly $3 billion per year. Millions of Anthem members experienced forced PBM transitions, disrupting prescription continuity and requiring new prior authorizations.
Post-merger layoffs eliminate 800+ positions tied to Anthem departure
Following the Cigna acquisition and Anthem's departure, Express Scripts eliminated over 800 additional positions across multiple facilities tied to the lost Anthem contract. Combined with the 456-person Columbus closure, more than 1,250 workers were displaced in a 12-month span while the merged entity pursued $600 million in 'synergy' savings. Employees reported that layoffs disproportionately targeted experienced pharmacists and support staff.
Express Scripts creates offshore GPO Ascent Health Services in Switzerland
Express Scripts established Ascent Health Services, a group purchasing organization based in Switzerland, to aggregate rebate negotiations. Critics alleged the offshore structure exploited Swiss tax rates and GPO safe harbor rules to avoid domestic PBM disclosure requirements while generating additional rebate revenue. The FTC's 2026 settlement would later require reshoring Ascent to the U.S.
Axios exposes Express Scripts pharmacy clawback practices
Axios reported on Express Scripts' systematic clawback practices, revealing how the PBM claws back millions of dollars per year from pharmacies after prescriptions are dispensed through 'quality' metrics and retroactive adjustments. Express Scripts managed pharmacy benefits for roughly 100 million people while maintaining opaque fee structures.
PBMs exploit regulatory gap as federal oversight remains absent
As of 2020, PBMs including Express Scripts operated in a regulatory vacuum — they were not classified as insurers, pharmacies, or fiduciaries, and no federal agency had clear jurisdiction over their business practices. While state legislatures began introducing PBM transparency bills, PCMA (of which Express Scripts was a leading member) successfully blocked or weakened most legislation through lobbying. Express Scripts leveraged this regulatory gap to expand spread pricing, DIR fees, and specialty drug markups without disclosure requirements.
Express Scripts and Prime Therapeutics announce major collaboration
Express Scripts struck a three-year deal with Prime Therapeutics, collectively owned by 18 Blue Cross Blue Shield plans covering 28 million members. The partnership gave Express Scripts additional negotiating leverage over retail pharmacies and pharmaceutical manufacturers, further concentrating market power in drug supply chain negotiations.
Cigna rebrands Express Scripts unit as Evernorth
Cigna rebranded its health services division, including Express Scripts, Accredo specialty pharmacy, and eviCore, under the unified Evernorth brand. The reorganization deepened vertical integration by consolidating PBM services, specialty pharmacy, and utilization management under one entity. The rebrand created additional brand confusion for patients navigating the healthcare system, who now had to understand the relationship between Cigna, Evernorth, Express Scripts, and Accredo. Evernorth gets approximately 90% of its business from external clients beyond Cigna's own plans.
Whistleblower lawsuit alleges TRICARE 'refill pill mill' fraud
A qui tam lawsuit was unsealed alleging Express Scripts operated a 'refill pill mill' that systematically over-dispensed medications to TRICARE beneficiaries from 2009 to 2018. The company's system allegedly sent 90-day refills at the 60-day mark, dispensing 73% more pills than prescribed annually and defrauding the Department of Defense of billions in excess costs.
Nearly 15,000 pharmacies drop from TRICARE network over reimbursement
Approximately 14,963 retail pharmacies left the Express Scripts TRICARE network after new contract terms lowered reimbursement rates to levels pharmacies said would force them to operate at a loss. The exodus impacted 400,000 military families who lost access to nearby pharmacies, with many forced to choose between finding new in-network pharmacies or using Express Scripts' Accredo mail-order option.
Cigna announces plans to cut approximately 2,000 jobs amid IT outsourcing
The Cigna Group disclosed plans to eliminate approximately 2,000 positions across its divisions including Evernorth/Express Scripts, part of ongoing cost reduction tied to the vertical integration strategy. Employee reports indicated that IT functions were increasingly outsourced to international contractors while remaining staff faced higher workloads. The layoffs came as Cigna reported record revenues and continued multi-billion-dollar stock buyback programs.
Ohio sues Express Scripts and Prime Therapeutics for collusion
Ohio filed suit against Express Scripts and Prime Therapeutics, alleging the two PBMs colluded to fix pharmacy reimbursement rates. Independent pharmacies in Wisconsin, Minnesota, and New Jersey filed parallel suits in October 2023. In January 2024, an arbitrator would find that Prime engaged in horizontal price-fixing with Express Scripts, awarding $10 million to the AIDS Healthcare Foundation.
Cigna announces $3.2 billion accelerated stock repurchase
The Cigna Group announced a $3.2 billion accelerated stock repurchase agreement, part of a plan to buy back at least $5 billion in stock during the first half of 2024. The company would ultimately repurchase approximately $7 billion in shares during 2024 while Express Scripts' parent simultaneously pursued cost-cutting initiatives.
FTC interim report finds top 3 PBMs control 80% of prescriptions
The FTC released its first interim PBM report finding that Express Scripts, CVS Caremark, and OptumRx process nearly 80% of all U.S. prescriptions and that their affiliated pharmacies capture nearly 70% of all specialty drug revenue. The report documented how PBMs use market dominance to inflate drug prices and impose unfair terms on independent pharmacies.
Express Scripts sues FTC over PBM report
Express Scripts filed suit against the FTC and its chair, alleging the agency's interim report on PBM practices was misleading and defamatory to the pharmacy benefit manager industry. The aggressive legal challenge against the regulator was unprecedented in PBM history and signaled the company's combative posture toward regulatory oversight.
Kentucky sues Express Scripts for role in opioid crisis
Kentucky Attorney General Russell Coleman filed suit against Express Scripts alleging the PBM conspired with opioid manufacturers to manipulate public perception of opioid safety, secured favorable formulary placement for opioids in exchange for rebates, eliminated prior authorization safeguards, and ignored patterns of widespread abuse. West Virginia filed a parallel suit in August 2025.
FTC sues Express Scripts and two other PBMs over insulin prices
The Federal Trade Commission filed an administrative action against Express Scripts, CVS Caremark, OptumRx, and their affiliated GPOs, alleging anticompetitive rebating practices that artificially inflated insulin drug list prices. The FTC found that PBMs pressured insulin manufacturers to compete on rebate size rather than net price, keeping a slice of inflated rebates while patients paid more at the pharmacy counter.
Express Scripts expands specialty pharmacy mandates through Accredo
Express Scripts expanded its list of specialty medications requiring dispensing through its owned Accredo pharmacy, adding dozens of specialty drugs for autoimmune conditions, cancer, and rare diseases. Patients who had been using independent specialty pharmacies were forced to transition to Accredo or face higher out-of-pocket costs. The mandates deepened lock-in by making patients dependent on Express Scripts' closed dispensing network while steering them through an enrollment process that obscured alternative options.
Express Scripts counter-sues FTC, challenging constitutional authority
Express Scripts filed a counter-suit against the FTC, challenging the agency's constitutional authority to bring the insulin pricing case. The legal challenge questioned whether the FTC's administrative enforcement structure violated due process. Express Scripts would ultimately abandon this challenge when it agreed to settle in February 2026.
Cigna increases share repurchase authorization by $10 billion
After walking away from a potential Humana merger, Cigna announced a $10 billion increase to its share repurchase program. For 2025, Cigna projected $9-10 billion in stock buybacks, potentially buying back 12% of outstanding shares. The massive buyback program coincided with ongoing cost-cutting and workforce reductions at subsidiary Express Scripts.
FTC second interim report reveals $7.3 billion in specialty drug markups
The FTC's second interim PBM staff report found that the three largest PBMs imposed markups of hundreds to thousands of percent on specialty generic drugs used to treat cancer, HIV, and other serious conditions, yielding over $7.3 billion in excess revenue between 2017 and 2022. PBMs earned an additional $1.4 billion in spread pricing on these drugs.
Michigan AG sues Express Scripts for pharmacy price-fixing conspiracy
Michigan Attorney General Dana Nessel filed an antitrust lawsuit against Express Scripts and Prime Therapeutics, alleging a long-running conspiracy to fix pharmacy reimbursement rates, eliminate competition in the retail pharmacy services market, and drive independent pharmacies out of business. The suit alleged Express Scripts controlled nearly 90% of the Michigan PBM market.
PCMA names Express Scripts executive as board chair
The Pharmaceutical Care Management Association named Adam Kautzner, head of Express Scripts, as chair of its board. As chair, Kautzner would oversee PCMA's strategy including defense of PBMs amid growing scrutiny. PCMA spent over $17.5 million on lobbying in 2024, opposing transparency legislation and rebate pass-through requirements.
Philadelphia sues Express Scripts over opioid crisis role
The City of Philadelphia filed a lawsuit against Express Scripts, CVS Caremark, and OptumRx alleging PBMs conspired with opioid manufacturers to increase prescribing and dispensing of opioids through favorable formulary placement in exchange for rebates. More than 12,000 people died of overdoses in Philadelphia between 2010 and 2023. The suit invoked RICO statutes.
FTC secures landmark settlement with Express Scripts
Express Scripts agreed to a landmark FTC settlement requiring fundamental changes to its business model. Key terms include eliminating spread pricing, passing manufacturer rebates through to patients at point of sale by 2028, adopting cost-plus reimbursement for independent pharmacies, reshoring the Ascent GPO from Switzerland to the U.S. (bringing over $750 billion in purchasing back domestically), and submitting to 10-year FTC monitoring. The settlement contained no financial penalties.
Cigna cuts 2,000 jobs while executing billions in buybacks
The Cigna Group announced plans to eliminate approximately 2,000 positions (about 3% of its 73,500-person workforce), disclosed alongside its 2025 earnings report showing $274.9 billion in revenue and approximately $6 billion in net income. The layoffs coincided with ongoing stock buyback programs totaling $9-10 billion annually, epitomizing shareholder extraction at the expense of workforce stability.
Evidence (37 citations)
D1: User Value Erosion
D2: Business Customer Exploitation
D3: Shareholder Extraction
D4: Lock-in & Switching Costs
D5: Twiddling & Algorithmic Opacity
D6: Dark Patterns
D7: Advertising & Monetization Pressure
D8: Competitive Conduct
D9: Labor & Governance
D10: Regulatory & Legal Posture
Scoring Log (4 entries)
Corrected D3/D9 layoff timing from 2024 to early 2026 (Cigna-wide, not Express Scripts-specific). Fixed CEO Cordani compensation from 'over $25M' to $23.3M (2024). Updated PCMA lobbying from $17.5M to ~$18M (up 20%, not 14%). Fixed 3 fabricated FTC evidence URLs to correct paths. Replaced 2 fabricated Fierce Healthcare/Modern Healthcare evidence URLs with verified sources. Fixed history entry format (removed non-standard event field, added source: current).